HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marcello Moccia Selected Research

Therapeutics

11/2023Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia.
6/2022Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
6/2022Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.
11/2021ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial.
10/2020Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
2/2020The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis.
8/2014Gender differences in non-motor symptoms in early Parkinson's disease: a 2-years follow-up study on previously untreated patients.
4/2013Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
1/2013Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marcello Moccia Research Topics

Disease

43Multiple Sclerosis
03/2024 - 01/2014
18Parkinson Disease (Parkinson's Disease)
12/2020 - 11/2012
8Cognitive Dysfunction
11/2023 - 02/2013
7Relapsing-Remitting Multiple Sclerosis
01/2022 - 01/2015
4COVID-19
01/2022 - 10/2020
4Inflammation (Inflammations)
11/2021 - 10/2017
3Infections
07/2022 - 10/2021
3Atrophy
07/2020 - 11/2019
3CADASIL
01/2018 - 01/2015
2Demyelinating Diseases (Demyelinating Disease)
11/2022 - 10/2017
2Pain (Aches)
10/2020 - 01/2019
2Progressive Multifocal Leukoencephalopathy
01/2017 - 01/2014
2Dementia (Dementias)
04/2016 - 05/2015
1Chronic Progressive Multiple Sclerosis
04/2024
1Lymphopenia (Lymphocytopenia)
11/2023
1Neurodegenerative Diseases (Neurodegenerative Disease)
11/2023
1Congenital Abnormalities (Deformity)
01/2023
1Radiculopathy (Radiculopathy, Cervical)
11/2022
1Myelitis
11/2022
1Optic Neuritis (Retrobulbar Neuritis)
11/2022
1Neuromyelitis Optica (Devic's Disease)
11/2022
1Communicable Diseases (Infectious Diseases)
07/2022
1Sudden Infant Death (SID)
01/2022
1Ganglion Cysts (Ganglion)
12/2021
1Opportunistic Infections (Opportunistic Infection)
10/2021
1Muscular Diseases (Myopathy)
01/2021
1Diplopia (Double Vision)
01/2021
1Strabismus (Squint)
01/2021
1Neuromuscular Junction Diseases
01/2021
1Oculomotor Nerve Diseases (Oculomotor Nerve Palsy)
01/2021
1Nervous System Diseases (Neurological Disorders)
01/2020
1Fatigue
01/2019
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2015
1Infarction (Infarctions)
01/2015
1Parkinsonian Disorders (Parkinsonism)
01/2015
1Tremor (Tremors)
11/2014
1Hypokinesia (Bradykinesia)
11/2014
1Nocturia
08/2014

Drug/Important Bio-Agent (IBA)

13Biomarkers (Surrogate Marker)IBA
01/2020 - 02/2013
6Uric Acid (Urate)IBA
12/2016 - 07/2014
5ocrelizumabIBA
03/2024 - 04/2021
4Retinaldehyde (Retinal)IBA
01/2023 - 11/2018
4Natalizumab (Tysabri)FDA Link
01/2023 - 01/2014
4Monoclonal AntibodiesIBA
01/2023 - 01/2022
4AntibodiesIBA
11/2022 - 10/2020
4CladribineFDA LinkGeneric
02/2022 - 01/2020
3COVID-19 VaccinesIBA
11/2023 - 01/2022
3Interferon-betaIBA
01/2021 - 08/2015
3InterferonsIBA
01/2018 - 01/2015
3Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA
05/2015 - 11/2012
2SphingosineIBA
11/2023 - 01/2022
2Fingolimod Hydrochloride (FTY720)FDA Link
11/2023 - 01/2023
2GadoliniumIBA
01/2023 - 02/2019
2Immunoglobulins (Immunoglobulin)IBA
01/2023 - 01/2022
2Rituximab (Mabthera)FDA Link
11/2022 - 04/2021
2Botulinum Toxins (Botulinum Toxin)IBA
11/2022 - 10/2020
2Interferon beta-1aFDA Link
11/2021 - 10/2017
2AntioxidantsIBA
11/2021 - 06/2016
2coenzyme Q10 (CoQ10)IBA
09/2019 - 01/2019
2Nonsense Codon (Nonsense Mutation)IBA
01/2015 - 01/2015
2SmokeIBA
01/2015 - 05/2014
1siponimodIBA
04/2024
1ozanimodIBA
11/2023
1Vitamin DFDA LinkGeneric
11/2023
1Dimethyl FumarateIBA
01/2023
1Myelin-Oligodendrocyte GlycoproteinIBA
11/2022
1AntigensIBA
07/2022
1Phosphates (Orthophosphate)IBA
01/2022
1Messenger RNA (mRNA)IBA
01/2022
1Neuroprotective AgentsIBA
11/2021
1CurcuminIBA
11/2021
1PhytochemicalsIBA
11/2021
1Alemtuzumab (Campath)FDA Link
10/2021
1Immunoglobulin G (IgG)IBA
12/2020
1Immunoglobulin M (IgM)IBA
12/2020
1Cytidine Diphosphate (CDP)IBA
07/2020
1nabiximols (Sativex)IBA
06/2020
1VS 215IBA
11/2019
1Atorvastatin (Lipitor)FDA Link
02/2019
1Notch3 ReceptorIBA
01/2018
12-toluenesulfonamide (OTS)IBA
08/2017
1Caffeine (No Doz)FDA LinkGeneric
11/2016
1BilirubinIBA
06/2016
1Vitamin KFDA Link
08/2015
1Cholecalciferol (Vitamin D3)FDA Link
08/2015
1Dopamine (Intropin)FDA LinkGeneric
05/2015
1Oxygen (Dioxygen)IBA
04/2015
1NitrogenIBA
04/2015
1Levodopa (L Dopa)FDA LinkGeneric
03/2015
1Cysteine (L-Cysteine)FDA Link
01/2015
1Proteins (Proteins, Gene)FDA Link
01/2015
12- carbomethoxy- 8- (3- fluoropropyl)- 3- (4- iodophenyl)tropaneIBA
11/2014
1C-Reactive ProteinIBA
01/2014
1ImmunosorbentsIBA
01/2014
1DNA (Deoxyribonucleic Acid)IBA
01/2014

Therapy/Procedure

9Therapeutics
11/2023 - 01/2013
2Injections
11/2022 - 05/2018
1Telescopes
01/2021
1Continuity of Patient Care
12/2020
1Activities of Daily Living (ADL)
10/2020